John Thomas Financial, an independent broker/dealer and investment-banking firm located in New York City’s Financial District, today announced its participation has raised USD40m in a private equity placement for Kadmon I, LLC, the investment vehicle for Kadmon’s operations, including Kadmon Corporation.
Kadmon, headquartered in New York City, is a privately held biopharmaceutical company pioneering medicines in oncology, infectious diseases, immunology and other serious diseases. The Company currently commercializes products for the treatment and management of hepatitis C and is advancing a robust pipeline of therapeutic candidates in various stages of development.
Proceeds from the equity placement will support Kadmon Corporation’s ongoing operations, and build the Company’s diversified research, development and commercial assets.
John Thomas Financial CEO ,Thomas Belesis (pictured), says he saw an exceptional opportunity with Kadmon, one that highlights John Thomas Financial’s core values. "Kadmon is breaking ground in the biopharmaceutical industry and we are proud to have a relationship with a company helping people fight serious disease," he says. "The company has built a new model for bringing innovative medicines to patients more rapidly and cost effectively."
